2vqj › Citations

Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain.

Bottomley MJ, Lo Surdo P, Di Giovine P, Cirillo A, Scarpelli R, Ferrigno F, Jones P, Neddermann P, De Francesco R, Steinkühler C, Gallinari P, Carfí A
J Biol Chem 283 26694-704 (2008)
Related entries: 2vqm, 2vqo, 2vqq, 2vqv, 2vqw

Cited: 167 times
EuropePMC logo PMID: 18614528

Abstract

Histone deacetylases (HDACs) regulate chromatin status and gene expression, and their inhibition is of significant therapeutic interest. To date, no biological substrate for class IIa HDACs has been identified, and only low activity on acetylated lysines has been demonstrated. Here, we describe inhibitor-bound and inhibitor-free structures of the histone deacetylase-4 catalytic domain (HDAC4cd) and of an HDAC4cd active site mutant with enhanced enzymatic activity toward acetylated lysines. The structures presented, coupled with activity data, provide the molecular basis for the intrinsically low enzymatic activity of class IIa HDACs toward acetylated lysines and reveal active site features that may guide the design of class-specific inhibitors. In addition, these structures reveal a conformationally flexible structural zinc-binding domain conserved in all class IIa enzymes. Importantly, either the mutation of residues coordinating the structural zinc ion or the binding of a class IIa selective inhibitor prevented the association of HDAC4 with the N-CoR.HDAC3 repressor complex. Together, these data suggest a key role of the structural zinc-binding domain in the regulation of class IIa HDAC functions.

Reviews - 2vqj mentioned but not cited (8)

  1. Targeting Metalloenzymes for Therapeutic Intervention. Chen AY, Adamek RN, Dick BL, Credille CV, Morrison CN, Cohen SM. Chem Rev 119 1323-1455 (2019)
  2. Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives. Andreoli F, Barbosa AJ, Parenti MD, Del Rio A. Curr Pharm Des 19 578-613 (2013)
  3. Computational studies on the histone deacetylases and the design of selective histone deacetylase inhibitors. Wang D. Curr Top Med Chem 9 241-256 (2009)
  4. Guidelines for the successful generation of protein-ligand complex crystals. Müller I. Acta Crystallogr D Struct Biol 73 79-92 (2017)
  5. Structural and chemical biology of deacetylases for carbohydrates, proteins, small molecules and histones. Bürger M, Chory J. Commun Biol 1 217 (2018)
  6. Non-Hydroxamate Zinc-Binding Groups as Warheads for Histone Deacetylases. Frühauf A, Meyer-Almes FJ. Molecules 26 5151 (2021)
  7. Regulation of Thermogenic Adipocyte Differentiation and Adaptive Thermogenesis Through Histone Acetylation. Ong BX, Brunmeir R, Zhang Q, Peng X, Idris M, Liu C, Xu F. Front Endocrinol (Lausanne) 11 95 (2020)
  8. Significance of Five-Membered Heterocycles in Human Histone Deacetylase Inhibitors. Frühauf A, Behringer M, Meyer-Almes FJ. Molecules 28 5686 (2023)

Articles - 2vqj mentioned but not cited (22)

  1. Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain. Bottomley MJ, Lo Surdo P, Di Giovine P, Cirillo A, Scarpelli R, Ferrigno F, Jones P, Neddermann P, De Francesco R, Steinkühler C, Gallinari P, Carfí A. J Biol Chem 283 26694-26704 (2008)
  2. Structural basis for the inhibition of histone deacetylase 8 (HDAC8), a key epigenetic player in the blood fluke Schistosoma mansoni. Marek M, Kannan S, Hauser AT, Moraes Mourão M, Caby S, Cura V, Stolfa DA, Schmidtkunz K, Lancelot J, Andrade L, Renaud JP, Oliveira G, Sippl W, Jung M, Cavarelli J, Pierce RJ, Romier C. PLoS Pathog 9 e1003645 (2013)
  3. Nuclear import of histone deacetylase 5 by requisite nuclear localization signal phosphorylation. Greco TM, Yu F, Guise AJ, Cristea IM. Mol Cell Proteomics 10 M110.004317 (2011)
  4. Insights into the Recruitment of Class IIa Histone Deacetylases (HDACs) to the SMRT/NCoR Transcriptional Repression Complex. Hudson GM, Watson PJ, Fairall L, Jamieson AG, Schwabe JWR. J Biol Chem 290 18237-18244 (2015)
  5. Screening of selective histone deacetylase inhibitors by proteochemometric modeling. Wu D, Huang Q, Zhang Y, Zhang Q, Liu Q, Gao J, Cao Z, Zhu R. BMC Bioinformatics 13 212 (2012)
  6. Novel Histone Deacetylase Class IIa Selective Substrate Radiotracers for PET Imaging of Epigenetic Regulation in the Brain. Bonomi R, Mukhopadhyay U, Shavrin A, Yeh HH, Majhi A, Dewage SW, Najjar A, Lu X, Cisneros GA, Tong WP, Alauddin MM, Liu RS, Mangner TJ, Turkman N, Gelovani JG. PLoS One 10 e0133512 (2015)
  7. Molecular modeling study on tunnel behavior in different histone deacetylase isoforms. Thangapandian S, John S, Lee Y, Arulalapperumal V, Lee KW. PLoS One 7 e49327 (2012)
  8. Comparative modeling and benchmarking data sets for human histone deacetylases and sirtuin families. Xia J, Tilahun EL, Kebede EH, Reid TE, Zhang L, Wang XS. J Chem Inf Model 55 374-388 (2015)
  9. Discovery of novel potential selective HDAC8 inhibitors by combine ligand-based, structure-based virtual screening and in-vitro biological evaluation. Debnath S, Debnath T, Bhaumik S, Majumdar S, Kalle AM, Aparna V. Sci Rep 9 17174 (2019)
  10. Discovery of novel N-substituted thiazolidinediones (TZDs) as HDAC8 inhibitors: in-silico studies, synthesis, and biological evaluation. Upadhyay N, Tilekar K, Jänsch N, Schweipert M, Hess JD, Henze Macias L, Mrowka P, Aguilera RJ, Choe JY, Meyer-Almes FJ, Ramaa CS. Bioorg Chem 100 103934 (2020)
  11. Identification of a better Homo sapiens Class II HDAC inhibitor through binding energy calculations and descriptor analysis. Tambunan US, Wulandari EK. BMC Bioinformatics 11 Suppl 7 S16 (2010)
  12. Thiol versus hydroxamate as zinc binding group in HDAC inhibition: An ab initio QM/MM molecular dynamics study. Gong W, Wu R, Zhang Y. J Comput Chem 36 2228-2235 (2015)
  13. Mutagenesis Study Reveals the Rim of Catalytic Entry Site of HDAC4 and -5 as the Major Binding Surface of SMRT Corepressor. Kim GS, Jung HE, Kim JS, Lee YC. PLoS One 10 e0132680 (2015)
  14. Epigallocatechin gallate inhibits HeLa cells by modulation of epigenetics and signaling pathways. Kedhari Sundaram M, Haque S, Somvanshi P, Bhardwaj T, Hussain A. 3 Biotech 10 484 (2020)
  15. Mechanistic Insights into Binding of Ligands with Thiazolidinedione Warhead to Human Histone Deacetylase 4. Schweipert M, Jänsch N, Upadhyay N, Tilekar K, Wozny E, Basheer S, Wurster E, Müller M, C S R, Meyer-Almes FJ. Pharmaceuticals (Basel) 14 1032 (2021)
  16. Switching the Switch: Ligand Induced Disulfide Formation in HDAC8. Jänsch N, Sugiarto WO, Muth M, Kopranovic A, Desczyk C, Ballweg M, Kirschhöfer F, Brenner-Weiss G, Meyer-Almes FJ. Chemistry 26 13249-13255 (2020)
  17. A Network Pharmacology Prediction and Molecular Docking-Based Strategy to Explore the Potential Pharmacological Mechanism of Astragalus membranaceus for Glioma. Feng Y, Zhu P, Wu D, Deng W. Int J Mol Sci 24 16306 (2023)
  18. Antitumor mechanisms of amino Acid hydroxyurea derivatives in the metastatic colon cancer model. Saban N, Stepanić V, Vučinić S, Horvatić A, Cindrić M, Perković I, Zorc B, Oršolić N, Mintas M, Pavelić K, Pavelić SK. Int J Mol Sci 14 23654-23671 (2013)
  19. Combined In Silico and In Vitro Analyses to Assess the Anticancer Potential of Thiazolidinedione-Thiosemicarbazone Hybrid Molecules. Paneth A, Kaproń B, Plech T, Paduch R, Trotsko N, Paneth P. Int J Mol Sci 24 17521 (2023)
  20. Discovery of New 2-Phenylamino-3-acyl-1,4-naphthoquinones as Inhibitors of Cancer Cells Proliferation: Searching for Intra-Cellular Targets Playing a Role in Cancer Cells Survival. Benites J, Valderrama JA, Contreras Á, Enríquez C, Pino-Rios R, Yáñez O, Buc Calderon P. Molecules 28 4323 (2023)
  21. Identification of potent HDAC 2 inhibitors using E-pharmacophore modelling, structure-based virtual screening and molecular dynamic simulation. Pai P, Kumar A, Shetty MG, Kini SG, Krishna MB, Satyamoorthy K, Babitha KS. J Mol Model 28 119 (2022)
  22. Non-oncology drug (meticrane) shows anti-cancer ability in synergy with epigenetic inhibitors and appears to be involved passively in targeting cancer cells. Wang Y, Sharma A, Ge F, Chen P, Yang Y, Liu H, Liu H, Zhao C, Mittal L, Asthana S, Schmidt-Wolf IGH. Front Oncol 13 1157366 (2023)


Reviews citing this publication (49)

  1. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Haberland M, Montgomery RL, Olson EN. Nat Rev Genet 10 32-42 (2009)
  2. New and emerging HDAC inhibitors for cancer treatment. West AC, Johnstone RW. J Clin Invest 124 30-39 (2014)
  3. Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Gryder BE, Sodji QH, Oyelere AK. Future Med Chem 4 505-524 (2012)
  4. HDAC4: mechanism of regulation and biological functions. Wang Z, Qin G, Zhao TC. Epigenomics 6 139-150 (2014)
  5. Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells. Wang L, de Zoeten EF, Greene MI, Hancock WW. Nat Rev Drug Discov 8 969-981 (2009)
  6. Structure, mechanism, and inhibition of histone deacetylases and related metalloenzymes. Lombardi PM, Cole KE, Dowling DP, Christianson DW. Curr Opin Struct Biol 21 735-743 (2011)
  7. Isoform-specific histone deacetylase inhibitors: the next step? Balasubramanian S, Verner E, Buggy JJ. Cancer Lett 280 211-221 (2009)
  8. Lysine Acetylation Goes Global: From Epigenetics to Metabolism and Therapeutics. Ali I, Conrad RJ, Verdin E, Ott M. Chem Rev 118 1216-1252 (2018)
  9. A short guide to histone deacetylases including recent progress on class II enzymes. Park SY, Kim JS. Exp Mol Med 52 204-212 (2020)
  10. Histone/protein deacetylases and T-cell immune responses. Akimova T, Beier UH, Liu Y, Wang L, Hancock WW. Blood 119 2443-2451 (2012)
  11. Histone deacetylases: structural determinants of inhibitor selectivity. Micelli C, Rastelli G. Drug Discov Today 20 718-735 (2015)
  12. HDAC4 as a potential therapeutic target in neurodegenerative diseases: a summary of recent achievements. Mielcarek M, Zielonka D, Carnemolla A, Marcinkowski JT, Guidez F. Front Cell Neurosci 9 42 (2015)
  13. Class IIa HDACs: from important roles in differentiation to possible implications in tumourigenesis. Clocchiatti A, Florean C, Brancolini C. J Cell Mol Med 15 1833-1846 (2011)
  14. HDAC8 substrates: Histones and beyond. Wolfson NA, Pitcairn CA, Fierke CA. Biopolymers 99 112-126 (2013)
  15. Mechanisms of action of tasquinimod on the tumour microenvironment. Raymond E, Dalgleish A, Damber JE, Smith M, Pili R. Cancer Chemother Pharmacol 73 1-8 (2014)
  16. Metabolism as a key to histone deacetylase inhibition. Rajendran P, Williams DE, Ho E, Dashwood RH. Crit Rev Biochem Mol Biol 46 181-199 (2011)
  17. The role of redox modulation of class II histone deacetylases in mediating pathological cardiac hypertrophy. Oka S, Ago T, Kitazono T, Zablocki D, Sadoshima J. J Mol Med (Berl) 87 785-791 (2009)
  18. Small molecule inhibitors of zinc-dependent histone deacetylases. Wagner FF, Weїwer M, Lewis MC, Holson EB. Neurotherapeutics 10 589-604 (2013)
  19. Detecting the emergence of novel, zoonotic viruses pathogenic to humans. Rosenberg R. Cell Mol Life Sci 72 1115-1125 (2015)
  20. Towards selective inhibition of histone deacetylase isoforms: what has been achieved, where we are and what will be next. Thaler F, Mercurio C. ChemMedChem 9 523-526 (2014)
  21. Structure, mechanism, and inhibition of the zinc-dependent histone deacetylases. Porter NJ, Christianson DW. Curr Opin Struct Biol 59 9-18 (2019)
  22. Epigenetic modulation of host: new insights into immune evasion by viruses. Adhya D, Basu A. J Biosci 35 647-663 (2010)
  23. Chemical and structural biology of protein lysine deacetylases. Yoshida M, Kudo N, Kosono S, Ito A. Proc Jpn Acad Ser B Phys Biol Sci 93 297-321 (2017)
  24. Selective class IIa HDAC inhibitors: myth or reality. Di Giorgio E, Gagliostro E, Brancolini C. Cell Mol Life Sci 72 73-86 (2015)
  25. Innovative Strategies for Selective Inhibition of Histone Deacetylases. Maolanon AR, Madsen AS, Olsen CA. Cell Chem Biol 23 759-768 (2016)
  26. Histone Deacetylases and their Inhibitors in Cancer Epigenetics. Hassell KN. Diseases 7 E57 (2019)
  27. Next-generation of selective histone deacetylase inhibitors. Yang F, Zhao N, Ge D, Chen Y. RSC Adv 9 19571-19583 (2019)
  28. Small-molecular modulators of cancer-associated epigenetic mechanisms. Itoh Y, Suzuki T, Miyata N. Mol Biosyst 9 873-896 (2013)
  29. The Class IIa histone deacetylase HDAC4 and neuronal function: Nuclear nuisance and cytoplasmic stalwart? Fitzsimons HL. Neurobiol Learn Mem 123 149-158 (2015)
  30. Beside the MEF2 axis: unconventional functions of HDAC4. Clocchiatti A, Di Giorgio E, Demarchi F, Brancolini C. Cell Signal 25 269-276 (2013)
  31. Recent advances in fluorination techniques and their anticipated impact on drug metabolism and toxicity. Murphy CD, Sandford G. Expert Opin Drug Metab Toxicol 11 589-599 (2015)
  32. Small-molecule chromatin-modifying agents: therapeutic applications. Mai A. Epigenomics 2 307-324 (2010)
  33. An overview of naturally occurring histone deacetylase inhibitors. Kim B, Hong J. Curr Top Med Chem 14 2759-2782 (2015)
  34. How the flexibility of human histone deacetylases influences ligand binding: an overview. Deschamps N, Simões-Pires CA, Carrupt PA, Nurisso A. Drug Discov Today 20 736-742 (2015)
  35. Therapeutic potential of isoform selective HDAC inhibitors for the treatment of schizophrenia. Weïwer M, Lewis MC, Wagner FF, Holson EB. Future Med Chem 5 1491-1508 (2013)
  36. Toward isozyme-selective inhibitors of histone deacetylase as therapeutic agents for the treatment of cancer. Ononye SN, van Heyst M, Falcone EM, Anderson AC, Wright DL. Pharm Pat Anal 1 207-221 (2012)
  37. Natural and Synthetic Macrocyclic Inhibitors of the Histone Deacetylase Enzymes. Maolanon AR, Kristensen HM, Leman LJ, Ghadiri MR, Olsen CA. Chembiochem 18 5-49 (2017)
  38. Nuclear Receptor Coactivators (NCOAs) and Corepressors (NCORs) in the Brain. Sun Z, Xu Y. Endocrinology 161 bqaa083 (2020)
  39. Drugging the schistosome zinc-dependent HDACs: current progress and future perspectives. Marek M, Oliveira G, Pierce RJ, Jung M, Sippl W, Romier C. Future Med Chem 7 783-800 (2015)
  40. The Role of Histone Acetylation-/Methylation-Mediated Apoptotic Gene Regulation in Hepatocellular Carcinoma. Rajan PK, Udoh UA, Sanabria JD, Banerjee M, Smith G, Schade MS, Sanabria J, Sodhi K, Pierre S, Xie Z, Shapiro JI, Sanabria J. Int J Mol Sci 21 E8894 (2020)
  41. Nuclear receptor corepressors in intellectual disability and autism. Kong Y, Zhou W, Sun Z. Mol Psychiatry 25 2220-2236 (2020)
  42. A review of tasquinimod in the treatment of advanced prostate cancer. Williamson SC, Hartley AE, Heer R. Drug Des Devel Ther 7 167-174 (2013)
  43. Structural determinants of affinity and selectivity in the binding of inhibitors to histone deacetylase 6. Osko JD, Christianson DW. Bioorg Med Chem Lett 30 127023 (2020)
  44. Critical review of non-histone human substrates of metal-dependent lysine deacetylases. Toro TB, Watt TJ. FASEB J 34 13140-13155 (2020)
  45. Management of double-refractory multiple myeloma. Meadows JP, Mark TM. Curr Hematol Malig Rep 8 253-260 (2013)
  46. A decade of the human genome sequence--how does the medicinal chemist benefit? Brunschweiger A, Hall J. ChemMedChem 7 194-203 (2012)
  47. Profiling technologies for the identification and characterization of small-molecule histone deacetylase inhibitors. Liao D. Drug Discov Today Technol 18 24-28 (2015)
  48. HDAC4 in cancer: A multitasking platform to drive not only epigenetic modifications. Cuttini E, Goi C, Pellarin E, Vida R, Brancolini C. Front Mol Biosci 10 1116660 (2023)
  49. A Role for Histone Deacetylases in the Biology and Treatment of Post-Traumatic Stress Disorder: What Do We Know and Where Do We Go from Here? Bonomi RE, Girgenti M, Krystal JH, Cosgrove KP. Complex Psychiatry 8 13-27 (2022)

Articles citing this publication (88)

  1. Chemical phylogenetics of histone deacetylases. Bradner JE, West N, Grachan ML, Greenberg EF, Haggarty SJ, Warnow T, Mazitschek R. Nat Chem Biol 6 238-243 (2010)
  2. Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group. Lobera M, Madauss KP, Pohlhaus DT, Wright QG, Trocha M, Schmidt DR, Baloglu E, Trump RP, Head MS, Hofmann GA, Murray-Thompson M, Schwartz B, Chakravorty S, Wu Z, Mander PK, Kruidenier L, Reid RA, Burkhart W, Turunen BJ, Rong JX, Wagner C, Moyer MB, Wells C, Hong X, Moore JT, Williams JD, Soler D, Ghosh S, Nolan MA. Nat Chem Biol 9 319-325 (2013)
  3. Structural studies of human histone deacetylase 8 and its site-specific variants complexed with substrate and inhibitors. Dowling DP, Gantt SL, Gattis SG, Fierke CA, Christianson DW. Biochemistry 47 13554-13563 (2008)
  4. HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration. Mielcarek M, Landles C, Weiss A, Bradaia A, Seredenina T, Inuabasi L, Osborne GF, Wadel K, Touller C, Butler R, Robertson J, Franklin SA, Smith DL, Park L, Marks PA, Wanker EE, Olson EN, Luthi-Carter R, van der Putten H, Beaumont V, Bates GP. PLoS Biol 11 e1001717 (2013)
  5. Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment. Isaacs JT, Antony L, Dalrymple SL, Brennen WN, Gerber S, Hammers H, Wissing M, Kachhap S, Luo J, Xing L, Björk P, Olsson A, Björk A, Leanderson T. Cancer Res 73 1386-1399 (2013)
  6. K+ efflux is required for histone H3 dephosphorylation by Listeria monocytogenes listeriolysin O and other pore-forming toxins. Hamon MA, Cossart P. Infect Immun 79 2839-2846 (2011)
  7. AMPK-HDAC5 pathway facilitates nuclear accumulation of HIF-1α and functional activation of HIF-1 by deacetylating Hsp70 in the cytosol. Chen S, Yin C, Lao T, Liang D, He D, Wang C, Sang N. Cell Cycle 14 2520-2536 (2015)
  8. Activation and inhibition of histone deacetylase 8 by monovalent cations. Gantt SL, Joseph CG, Fierke CA. J Biol Chem 285 6036-6043 (2010)
  9. Dissociation of muscle insulin sensitivity from exercise endurance in mice by HDAC3 depletion. Hong S, Zhou W, Fang B, Lu W, Loro E, Damle M, Ding G, Jager J, Zhang S, Zhang Y, Feng D, Chu Q, Dill BD, Molina H, Khurana TS, Rabinowitz JD, Lazar MA, Sun Z. Nat Med 23 223-234 (2017)
  10. Eating disorder predisposition is associated with ESRRA and HDAC4 mutations. Cui H, Moore J, Ashimi SS, Mason BL, Drawbridge JN, Han S, Hing B, Matthews A, McAdams CJ, Darbro BW, Pieper AA, Waller DA, Xing C, Lutter M. J Clin Invest 123 4706-4713 (2013)
  11. Histone deacetylase 9 (HDAC9) regulates the functions of the ATDC (TRIM29) protein. Yuan Z, Peng L, Radhakrishnan R, Seto E. J Biol Chem 285 39329-39338 (2010)
  12. Structures of metal-substituted human histone deacetylase 8 provide mechanistic inferences on biological function . Dowling DP, Gattis SG, Fierke CA, Christianson DW. Biochemistry 49 5048-5056 (2010)
  13. A direct HDAC4-MAP kinase crosstalk activates muscle atrophy program. Choi MC, Cohen TJ, Barrientos T, Wang B, Li M, Simmons BJ, Yang JS, Cox GA, Zhao Y, Yao TP. Mol Cell 47 122-132 (2012)
  14. Zinc chelation with hydroxamate in histone deacetylases modulated by water access to the linker binding channel. Wu R, Lu Z, Cao Z, Zhang Y. J Am Chem Soc 133 6110-6113 (2011)
  15. The histone deacetylase HDAC4 regulates long-term memory in Drosophila. Fitzsimons HL, Schwartz S, Given FM, Scott MJ. PLoS One 8 e83903 (2013)
  16. Discovery of potent and selective histone deacetylase inhibitors via focused combinatorial libraries of cyclic alpha3beta-tetrapeptides. Olsen CA, Ghadiri MR. J Med Chem 52 7836-7846 (2009)
  17. Effects of novel HDAC inhibitors on urothelial carcinoma cells. Kaletsch A, Pinkerneil M, Hoffmann MJ, Jaguva Vasudevan AA, Wang C, Hansen FK, Wiek C, Hanenberg H, Gertzen C, Gohlke H, Kassack MU, Kurz T, Schulz WA, Niegisch G. Clin Epigenetics 10 100 (2018)
  18. Synthesis of 1,2-benzisoxazole tethered 1,2,3-triazoles that exhibit anticancer activity in acute myeloid leukemia cell lines by inhibiting histone deacetylases, and inducing p21 and tubulin acetylation. Ashwini N, Garg M, Mohan CD, Fuchs JE, Rangappa S, Anusha S, Swaroop TR, Rakesh KS, Kanojia D, Madan V, Bender A, Koeffler HP, Basappa, Rangappa KS. Bioorg Med Chem 23 6157-6165 (2015)
  19. Histone deacetylase 4 alters cartilage homeostasis in human osteoarthritis. Lu J, Sun Y, Ge Q, Teng H, Jiang Q. BMC Musculoskelet Disord 15 438 (2014)
  20. Tropolones as lead-like natural products: the development of potent and selective histone deacetylase inhibitors. Ononye SN, VanHeyst MD, Oblak EZ, Zhou W, Ammar M, Anderson AC, Wright DL. ACS Med Chem Lett 4 757-761 (2013)
  21. Plants Release Precursors of Histone Deacetylase Inhibitors to Suppress Growth of Competitors. Venturelli S, Belz RG, Kämper A, Berger A, von Horn K, Wegner A, Böcker A, Zabulon G, Langenecker T, Kohlbacher O, Barneche F, Weigel D, Lauer UM, Bitzer M, Becker C. Plant Cell 27 3175-3189 (2015)
  22. Loss of the putative catalytic domain of HDAC4 leads to reduced thermal nociception and seizures while allowing normal bone development. Rajan I, Savelieva KV, Ye GL, Wang CY, Malbari MM, Friddle C, Lanthorn TH, Zhang W. PLoS One 4 e6612 (2009)
  23. Structure of prokaryotic polyamine deacetylase reveals evolutionary functional relationships with eukaryotic histone deacetylases. Lombardi PM, Angell HD, Whittington DA, Flynn EF, Rajashankar KR, Christianson DW. Biochemistry 50 1808-1817 (2011)
  24. HDAC4 does not act as a protein deacetylase in the postnatal murine brain in vivo. Mielcarek M, Seredenina T, Stokes MP, Osborne GF, Landles C, Inuabasi L, Franklin SA, Silva JC, Luthi-Carter R, Beaumont V, Bates GP. PLoS One 8 e80849 (2013)
  25. The effect of various zinc binding groups on inhibition of histone deacetylases 1-11. Madsen AS, Kristensen HM, Lanz G, Olsen CA. ChemMedChem 9 614-626 (2014)
  26. Role of salt-induced kinase 1 in androgen neuroprotection against cerebral ischemia. Cheng J, Uchida M, Zhang W, Grafe MR, Herson PS, Hurn PD. J Cereb Blood Flow Metab 31 339-350 (2011)
  27. Targeting Lysine Deacetylases (KDACs) in Parasites. Wang Q, Rosa BA, Nare B, Powell K, Valente S, Rotili D, Mai A, Marshall GR, Mitreva M. PLoS Negl Trop Dis 9 e0004026 (2015)
  28. Structural basis for the design and synthesis of selective HDAC inhibitors. Di Micco S, Chini MG, Terracciano S, Bruno I, Riccio R, Bifulco G. Bioorg Med Chem 21 3795-3807 (2013)
  29. Entropy as a Driver of Selectivity for Inhibitor Binding to Histone Deacetylase 6. Porter NJ, Wagner FF, Christianson DW. Biochemistry 57 3916-3924 (2018)
  30. Modulation of Nerve Injury-induced HDAC4 Cytoplasmic Retention Contributes to Neuropathic Pain in Rats. Lin TB, Hsieh MC, Lai CY, Cheng JK, Chau YP, Ruan T, Chen GD, Peng HY. Anesthesiology 123 199-212 (2015)
  31. Next generation histone deacetylase inhibitors: the answer to the search for optimized epigenetic therapies? Thaler F, Minucci S. Expert Opin Drug Discov 6 393-404 (2011)
  32. miR-9 Upregulation Integrates Post-ischemic Neuronal Survival and Regeneration In Vitro. Nampoothiri SS, Rajanikant GK. Cell Mol Neurobiol 39 223-240 (2019)
  33. Synthesis of N-hydroxycinnamides capped with a naturally occurring moiety as inhibitors of histone deacetylase. Huang WJ, Chen CC, Chao SW, Lee SS, Hsu FL, Lu YL, Hung MF, Chang CI. ChemMedChem 5 598-607 (2010)
  34. Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agents. He R, Chen Y, Chen Y, Ougolkov AV, Zhang JS, Savoy DN, Billadeau DD, Kozikowski AP. J Med Chem 53 1347-1356 (2010)
  35. Potent, Selective, and CNS-Penetrant Tetrasubstituted Cyclopropane Class IIa Histone Deacetylase (HDAC) Inhibitors. Luckhurst CA, Breccia P, Stott AJ, Aziz O, Birch HL, Bürli RW, Hughes SJ, Jarvis RE, Lamers M, Leonard PM, Matthews KL, McAllister G, Pollack S, Saville-Stones E, Wishart G, Yates D, Dominguez C. ACS Med Chem Lett 7 34-39 (2016)
  36. Zinc and Its Transporters in Epigenetics. Brito S, Lee MG, Bin BH, Lee JS. Mol Cells 43 323-330 (2020)
  37. In silico modification of suberoylanilide hydroxamic acid (SAHA) as potential inhibitor for class II histone deacetylase (HDAC). Tambunan US, Bramantya N, Parikesit AA. BMC Bioinformatics 12 Suppl 13 S23 (2011)
  38. Structural and Functional Influence of the Glycine-Rich Loop G302GGGY on the Catalytic Tyrosine of Histone Deacetylase 8. Porter NJ, Christianson NH, Decroos C, Christianson DW. Biochemistry 55 6718-6729 (2016)
  39. TGF-β1 stimulates HDAC4 nucleus-to-cytoplasm translocation and NADPH oxidase 4-derived reactive oxygen species in normal human lung fibroblasts. Guo W, Saito S, Sanchez CG, Zhuang Y, Gongora Rosero RE, Shan B, Luo F, Lasky JA. Am J Physiol Lung Cell Mol Physiol 312 L936-L944 (2017)
  40. Fragment based G-QSAR and molecular dynamics based mechanistic simulations into hydroxamic-based HDAC inhibitors against spinocerebellar ataxia. Sinha S, Tyagi C, Goyal S, Jamal S, Somvanshi P, Grover A. J Biomol Struct Dyn 34 2281-2295 (2016)
  41. Histone deacetylases regulate multicellular development in the social amoeba Dictyostelium discoideum. Sawarkar R, Visweswariah SS, Nellen W, Nanjundiah V. J Mol Biol 391 833-848 (2009)
  42. Structural basis of the specific interaction of SMRT corepressor with histone deacetylase 4. Park SY, Kim GS, Hwang HJ, Nam TH, Park HS, Song J, Jang TH, Lee YC, Kim JS. Nucleic Acids Res 46 11776-11788 (2018)
  43. Discovery of potent HDAC inhibitors based on chlamydocin with inhibitory effects on cell migration. Wang S, Li X, Wei Y, Xiu Z, Nishino N. ChemMedChem 9 627-637 (2014)
  44. New organofluorine building blocks: inhibition of the malarial aspartic proteases plasmepsin II and IV by alicyclic alpha,alpha-difluoroketone hydrates. Fäh C, Hardegger LA, Baitsch L, Schweizer WB, Meyer S, Bur D, Diederich F. Org Biomol Chem 7 3947-3957 (2009)
  45. Probing phosphorylation-dependent protein interactions within functional domains of histone deacetylase 5 (HDAC5). Guise AJ, Mathias RA, Rowland EA, Yu F, Cristea IM. Proteomics 14 2156-2166 (2014)
  46. Synthesis of Novel Structural Hybrids between Aza-Heterocycles and Azelaic Acid Moiety with a Specific Activity on Osteosarcoma Cells. Micheletti G, Calonghi N, Farruggia G, Strocchi E, Palmacci V, Telese D, Bordoni S, Frisco G, Boga C. Molecules 25 E404 (2020)
  47. The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position. Choi SE, Pflum MK. Bioorg Med Chem Lett 22 7084-7086 (2012)
  48. Synthesis of a new trifluoromethylketone analogue of l-arginine and contrasting inhibitory activity against human arginase I and histone deacetylase 8. Ilies M, Dowling DP, Lombardi PM, Christianson DW. Bioorg Med Chem Lett 21 5854-5858 (2011)
  49. X-ray Crystallographic Snapshots of Substrate Binding in the Active Site of Histone Deacetylase 10. Herbst-Gervasoni CJ, Christianson DW. Biochemistry 60 303-313 (2021)
  50. Design, Synthesis, and Evaluation of Polyamine Deacetylase Inhibitors, and High-Resolution Crystal Structures of Their Complexes with Acetylpolyamine Amidohydrolase. Decroos C, Christianson DW. Biochemistry 54 4692-4703 (2015)
  51. Mechanistic Insights into the Binding of Class IIa HDAC Inhibitors toward Spinocerebellar Ataxia Type-2: A 3D-QSAR and Pharmacophore Modeling Approach. Sinha S, Goyal S, Somvanshi P, Grover A. Front Neurosci 10 606 (2016)
  52. Phosphorylation of Histone Deacetylase 8: Structural and Mechanistic Analysis of the Phosphomimetic S39E Mutant. Welker Leng KR, Castañeda CA, Decroos C, Islam B, Haider SM, Christianson DW, Fierke CA. Biochemistry 58 4480-4493 (2019)
  53. Synthesis and evaluation of N⁸-acetylspermidine analogues as inhibitors of bacterial acetylpolyamine amidohydrolase. Decroos C, Bowman CM, Christianson DW. Bioorg Med Chem 21 4530-4540 (2013)
  54. Multiscale modeling of the causal functional roles of nsSNPs in a genome-wide association study: application to hypoxia. Xie L, Ng C, Ali T, Valencia R, Ferreira BL, Xue V, Tanweer M, Zhou D, Haddad GG, Bourne PE, Xie L. BMC Genomics 14 Suppl 3 S9 (2013)
  55. Novel cinnamyl hydroxyamides and 2-aminoanilides as histone deacetylase inhibitors: apoptotic induction and cytodifferentiation activity. Valente S, Tardugno M, Conte M, Cirilli R, Perrone A, Ragno R, Simeoni S, Tramontano A, Massa S, Nebbioso A, Miceli M, Franci G, Brosch G, Altucci L, Mai A. ChemMedChem 6 698-712 (2011)
  56. Structural Characterization of the SMRT Corepressor Interacting with Histone Deacetylase 7. Desravines DC, Serna Martin I, Schneider R, Mas PJ, Aleksandrova N, Jensen MR, Blackledge M, Hart DJ. Sci Rep 7 3678 (2017)
  57. Synthesis, evaluation and molecular modeling of cyclic tetrapeptide histone deacetylase inhibitors as anticancer agents. Huang D, Li X, Sun L, Xiu Z, Nishino N. J Pept Sci 18 242-251 (2012)
  58. A novel amidohydrolase (DmhA) from Sphingomonas sp. that can hydrolyze the organophosphorus pesticide dimethoate to dimethoate carboxylic acid and methylamine. Chen Q, Chen K, Ni H, Zhuang W, Wang H, Zhu J, He Q, He J. Biotechnol Lett 38 703-710 (2016)
  59. Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment. Isaacs JT, Dalrymple SL, Rosen DM, Hammers H, Olsson A, Leanderson T. Oncotarget 5 8093-8106 (2014)
  60. Inhibition mechanism of SAHA in HDAC: a revisit. Zhou J, Wu R, Luo HB. Phys Chem Chem Phys 17 29483-29488 (2015)
  61. Reconstitution of Mammalian Enzymatic Deacylation Reactions in Live Bacteria Using Native Acylated Substrates. Avrahami EM, Levi S, Zajfman E, Regev C, Ben-David O, Arbely E. ACS Synth Biol 7 2348-2354 (2018)
  62. Vorinostat-like molecules as structural, stereochemical, and pharmacological tools. Hanessian S, Auzzas L, Larsson A, Zhang J, Giannini G, Gallo G, Ciacci A, Cabri W. ACS Med Chem Lett 1 70-74 (2010)
  63. Developing consensus 3D-QSAR and pharmacophore models for several beta-secretase, farnesyl transferase and histone deacetylase inhibitors. Wei HY, Chen GJ, Chen CL, Lin TH. J Mol Model 18 675-692 (2012)
  64. Histone deacetylase inhibitors derived from 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine and related heterocycles selective for the HDAC6 isoform. Blackburn C, Barrett C, Brunson M, Chin J, England D, Garcia K, Gigstad K, Gould A, Gutierrez J, Hoar K, Rowland RS, Tsu C, Ringeling J, Wager K, Xu H. Bioorg Med Chem Lett 24 5450-5454 (2014)
  65. Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid. Bieliauskas AV, Weerasinghe SV, Negmeldin AT, Pflum MK. Arch Pharm (Weinheim) 349 373-382 (2016)
  66. A histone deacetylase-dependent screen in yeast. Weerasinghe SV, Wambua M, Pflum MK. Bioorg Med Chem 18 7586-7592 (2010)
  67. Approaches for Studying the Subcellular Localization, Interactions, and Regulation of Histone Deacetylase 5 (HDAC5). Guise AJ, Cristea IM. Methods Mol Biol 1436 47-84 (2016)
  68. Aromatic side-chain flips orchestrate the conformational sampling of functional loops in human histone deacetylase 8. Shukla VK, Siemons L, Gervasio FL, Hansen DF. Chem Sci 12 9318-9327 (2021)
  69. Lysine Deacetylase Substrate Selectivity: A Dynamic Ionic Interaction Specific to KDAC8. Toro TB, Swanier JS, Bezue JA, Broussard CG, Watt TJ. Biochemistry 60 2524-2536 (2021)
  70. Purification of metal-dependent lysine deacetylases with consistently high activity. Toro TB, Painter RG, Haynes RA, Glotser EY, Bratton MR, Bryant JR, Nichols KA, Matthew-Onabanjo AN, Matthew AN, Bratcher DR, Perry CD, Watt TJ. Protein Expr Purif 141 1-6 (2018)
  71. Rapid Fluorescent-Based Detection of New Delhi Metallo-β-Lactamases by Photo-Cross-Linking Using Conjugates of Azidonaphthalimide and Zinc(II)-Chelating Motifs. Singha M, Kumar G, Jain D, Kumar N G, Ray D, Ghosh AS, Basak A. ACS Omega 4 10891-10898 (2019)
  72. Structure and Function of the Acetylpolyamine Amidohydrolase from the Deep Earth Halophile Marinobacter subterrani. Osko JD, Roose BW, Shinsky SA, Christianson DW. Biochemistry 58 3755-3766 (2019)
  73. Structure of Arabidopsis HISTONE DEACETYLASE15. Chen CY, Tu YT, Hsu JC, Hung HC, Liu TC, Lee YH, Chou CC, Cheng YS, Wu K. Plant Physiol 184 1585-1600 (2020)
  74. Transcriptomic and genomic studies classify NKL54 as a histone deacetylase inhibitor with indirect influence on MEF2-dependent transcription. Minisini M, Di Giorgio E, Kerschbamer E, Dalla E, Faggiani M, Franforte E, Meyer-Almes FJ, Ragno R, Antonini L, Mai A, Fiorentino F, Fiorentino F, Rotili D, Chinellato M, Perin S, Cendron L, Weichenberger CX, Angelini A, Brancolini C. Nucleic Acids Res 50 2566-2586 (2022)
  75. Development of Coumarin-Based Hydroxamates as Histone Deacetylase Inhibitors with Antitumor Activities. Zhao N, Yang F, Han L, Qu Y, Ge D, Zhang H. Molecules 25 E717 (2020)
  76. Discovery of N-(2-Amino-4-Fluorophenyl)-4-[bis-(2-Chloroethyl)-Amino]-Benzamide as a Potent HDAC3 Inhibitor. Chen Y, Feng J, Hu Y, Wang X, Song W, Zhang L. Front Oncol 10 592385 (2020)
  77. Regulation of histone deacetylase 3 by metal cations and 10-hydroxy-2E-decenoic acid: Possible epigenetic mechanisms of queen-worker bee differentiation. Polsinelli GA, Yu HD. PLoS One 13 e0204538 (2018)
  78. Role of Scl39a13/ZIP13 in cardiovascular homeostasis. Hara T, Yamada I, Ohashi T, Tamura M, Hijikata A, Watanabe T, Gao M, Ito K, Kawamata S, Azuma S, Yoshigai E, Sumiyoshi Y, Yasuhiro N, Ohara O, Santos HGD, Fukada T. PLoS One 17 e0276452 (2022)
  79. Conformational dynamics and allosteric effect modulated by the unique zinc-binding motif in class IIa HDACs. Liu H, Zhang F, Wang K, Tang X, Wu R. Phys Chem Chem Phys 21 12173-12183 (2019)
  80. Determination of the binding mechanism of histone deacetylase inhibitors. Meyer-Almes FJ. Chem Biol Drug Des 93 1214-1250 (2019)
  81. Evidence that HDAC7 acts as an epigenetic "reader" of AR acetylation through NCoR-HDAC3 dissociation. Zhang Y, Andrade R, Hanna AA, Pflum MKH. Cell Chem Biol 29 1162-1173.e5 (2022)
  82. Four New Anthraquinones with Histone Deacetylase Inhibitory Activity from Ventilago denticulata Roots. Hangsamai N, Photai K, Mahaamnart T, Kanokmedhakul S, Kanokmedhakul K, Senawong T, Pitchuanchom S, Nontakitticharoen M. Molecules 27 1088 (2022)
  83. Histone de-acetylase inhibitors: a promising future for cancer treatment? Khan RS, Hameed H, Bhutta RA, Kazi AN, Riaz H. Infect Agent Cancer 8 10 (2013)
  84. Kinetic Characterization of Human Histone Deacetylase 8 With Medium-Chain Fatty Acyl Lysine. Yoo H, Polsinelli GA. Epigenet Insights 14 25168657211065685 (2021)
  85. Phenolic compounds as histone deacetylase inhibitors: binding propensity and interaction insights from molecular docking and dynamics simulations. Uba AI, Zengin G. Amino Acids 55 579-593 (2023)
  86. Rational design of metabolically stable HDAC inhibitors: An overhaul of trifluoromethyl ketones. Riddhidev B, Endri K, Sabitri L, Kotsull Lauren N, Nishanth K, Dragan I, Mary Kay H P, James S, William T, L M Viranga T. Eur J Med Chem 244 114807 (2022)
  87. Systematic Analysis of Lysine Acetylation Reveals Diverse Functions in Azorhizobium caulinodans Strain ORS571. Liu Y, Liu X, Dong X, Yin Z, Xie Z, Luo Y. Microbiol Spectr 11 e0353922 (2023)
  88. Third generation quinoline-3-carboxamide transcriptional disrupter of HDAC4, HIF-1α, and MEF-2 signaling for metastatic castration-resistant prostate cancer. Isaacs JT, Dalrymple SL, Antony L, Marc Rosen D, Coleman IM, Nelson PS, Kostova M, Murray IA, Perdew GH, Denmeade SR, Akinboye ES, Brennen WN. Prostate 83 1470-1493 (2023)


Quick links